Overview of first-line combined hormonal contraception
| Hormonal contraception | Duration of use (months) | n |
|---|---|---|
| Transdermal: 0.75 mg EE+6.00 mg norelgestromin | 27, 63, 70 | 3* |
| Intravaginal: 2.70 mg EE+11.70 mg etonogestrel | 32 | 1 |
| Monophasic oral: 0.03 mg EE+3.00 mg drospirenone | 16 | 1 |
| Monophasic oral: 0.02 mg EE+0.15 mg desogestrel | 62 | 1 |
| Biphasic oral: 0.04/0.30 mg EE+0.025/0.125 mg desogestrel | 26 | 1 |
| Triphasic oral: 0.03/0.04/0.03 mg EE+0.05/0.07/0.1 mg gestodene | 47 | 1 |
*One patient switched from a transdermal to an intravaginal mode of delivery (see text for details).
EE, ethinylestradiol.